Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents.

Saha MN, Chen Y, Chen MH, Chen G, Chang H.

Br J Cancer. 2014 Apr 29;110(9):2224-31. doi: 10.1038/bjc.2014.164. Epub 2014 Apr 1.

2.

PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.

Saha MN, Jiang H, Yang Y, Reece D, Chang H.

Mol Cancer Ther. 2013 Nov;12(11):2331-41. doi: 10.1158/1535-7163.MCT-12-1166. Epub 2013 Sep 12.

3.

Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents.

Leiba M, Jakubikova J, Klippel S, Mitsiades CS, Hideshima T, Tai YT, Leiba A, Pines M, Richardson PG, Nagler A, Anderson KC.

Br J Haematol. 2012 Jun;157(6):718-31. doi: 10.1111/j.1365-2141.2012.09120.x. Epub 2012 Apr 26.

4.

Acute cytotoxicity of MIRA-1/NSC19630, a mutant p53-reactivating small molecule, against human normal and cancer cells via a caspase-9-dependent apoptosis.

Bou-Hanna C, Jarry A, Lode L, Schmitz I, Schulze-Osthoff K, Kury S, Bezieau S, Mosnier JF, Laboisse CL.

Cancer Lett. 2015 Apr 10;359(2):211-7. doi: 10.1016/j.canlet.2015.01.014. Epub 2015 Jan 21.

PMID:
25617798
5.

Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells.

Rathos MJ, Khanwalkar H, Joshi K, Manohar SM, Joshi KS.

BMC Cancer. 2013 Jan 23;13:29. doi: 10.1186/1471-2407-13-29.

6.

Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.

Wang C, Gao D, Guo K, Kang X, Jiang K, Sun C, Li Y, Sun L, Shu H, Jin G, Sun H, Wu W, Liu Y.

BMC Cancer. 2012 May 4;12:166. doi: 10.1186/1471-2407-12-166.

7.

Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.

Tassone P, Neri P, Burger R, Savino R, Shammas M, Catley L, Podar K, Chauhan D, Masciari S, Gozzini A, Tagliaferri P, Venuta S, Munshi NC, Anderson KC.

Clin Cancer Res. 2005 Jun 1;11(11):4251-8.

8.

The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.

Bono C, Karlin L, Harel S, Mouly E, Labaume S, Galicier L, Apcher S, Sauvageon H, Fermand JP, Bories JC, Arnulf B.

Haematologica. 2012 Jul;97(7):1101-9. doi: 10.3324/haematol.2011.049981. Epub 2012 Jan 22.

9.

Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo.

Escalante AM, McGrath RT, Karolak MR, Dorr RT, Lynch RM, Landowski TH.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1567-76. doi: 10.1007/s00280-013-2156-3. Epub 2013 Apr 10.

10.

RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses.

Saha MN, Jiang H, Mukai A, Chang H.

Mol Cancer Ther. 2010 Nov;9(11):3041-51. doi: 10.1158/1535-7163.MCT-10-0471. Epub 2010 Nov 9.

11.

Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs.

Bykov VJ, Issaeva N, Zache N, Shilov A, Hultcrantz M, Bergman J, Selivanova G, Wiman KG.

J Biol Chem. 2005 Aug 26;280(34):30384-91. Epub 2005 Jul 1.

12.

The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.

Munugalavadla V, Mariathasan S, Slaga D, Du C, Berry L, Del Rosario G, Yan Y, Boe M, Sun L, Friedman LS, Chesi M, Leif Bergsagel P, Ebens A.

Oncogene. 2014 Jan 16;33(3):316-25. doi: 10.1038/onc.2012.594. Epub 2013 Jan 14.

PMID:
23318440
13.

Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways.

Lunghi P, Giuliani N, Mazzera L, Lombardi G, Ricca M, Corradi A, Cantoni AM, Salvatore L, Riccioni R, Costanzo A, Testa U, Levrero M, Rizzoli V, Bonati A.

Blood. 2008 Sep 15;112(6):2450-62. doi: 10.1182/blood-2007-10-114348. Epub 2008 Jun 26.

14.

MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.

Hideshima T, Neri P, Tassone P, Yasui H, Ishitsuka K, Raje N, Chauhan D, Podar K, Mitsiades C, Dang L, Munshi N, Richardson P, Schenkein D, Anderson KC.

Clin Cancer Res. 2006 Oct 1;12(19):5887-94.

15.

Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine.

Hariharan K, Chu P, Murphy T, Clanton D, Berquist L, Molina A, Ho SN, Vega MI, Bonavida B.

Int J Oncol. 2013 Aug;43(2):670-6. doi: 10.3892/ijo.2013.1986. Epub 2013 Jun 13.

16.
17.

Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo.

Zuco V, De Cesare M, Cincinelli R, Nannei R, Pisano C, Zaffaroni N, Zunino F.

PLoS One. 2011;6(12):e29085. doi: 10.1371/journal.pone.0029085. Epub 2011 Dec 14.

18.

Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization.

Udi J, Schüler J, Wider D, Ihorst G, Catusse J, Waldschmidt J, Schnerch D, Follo M, Wäsch R, Engelhardt M.

Br J Haematol. 2013 Apr;161(1):104-16. doi: 10.1111/bjh.12226. Epub 2013 Feb 6.

PMID:
23384035
19.

Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.

Ye S, Yang W, Wang Y, Ou W, Ma Q, Yu C, Ren J, Zhong G, Shi H, Yuan Z, Su X, Zhu W.

Int J Mol Med. 2013 Jan;31(1):33-42. doi: 10.3892/ijmm.2012.1171. Epub 2012 Nov 1.

PMID:
23128378
20.

Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.

Santo L, Hideshima T, Cirstea D, Bandi M, Nelson EA, Gorgun G, Rodig S, Vallet S, Pozzi S, Patel K, Unitt C, Squires M, Hu Y, Chauhan D, Mahindra A, Munshi NC, Anderson KC, Raje N.

Clin Cancer Res. 2011 May 15;17(10):3259-71. doi: 10.1158/1078-0432.CCR-10-3012. Epub 2011 Mar 23.

Supplemental Content

Support Center